LAG3 and melanoma: Other examples include the anti-TIGIT antibody tiragolumab with significant activity in a specific expansion cohort of NSCLC patients (50% ORR and 80% disease control rate) (68) or the anti-LAG3 antibody relatlimab that demonstrated clinical activity in later treatment lines in melanoma before being explored in first-line (69).